Neurotrope jumps in the Alzheimer’s solution chase, amid Biogen’s, Eisai’s dropping aducanunab trial

Neurotrope said Friday, commenting Biogen Inc.’s decision to discontinue its global Phase 3 trials of aducanunab in Alzheimer’s disease, Phase 2 clinical trial using its drug Bryostatin during the second half of 2019.

Neurotrope CEO, Dr. Charles Ryan, express sadness to the news that Biogen and Eisai’s efforts have fallen short.

“We, as a global society, are all in this fight together as we search for a cure for this devastating disease that is touching so many lives. Repeated attempts to treat or even slow the relentless progression of AD by targeting amyloid plaque in patient’s brains continues to lead to disappointing outcomes.”

Ryan said that the promising data from Neurotrope’s previous exploratory Phase 2 trial showed greater than baseline improvements in Severe Impairment Battery (SIB) scores for patients in the 20 µg Bryostatin-1 dose group, suggesting the potential to translate Bryostatin’s neurorestorative properties in the clinic. He noted that Neurotrope will be releasing results of our confirmatory Phase 2 clinical trial using our drug Bryostatin during the second half of 2019.

This is another comment, as pharmaceutical daily has reported on ProMIS’s comment on the same case.